SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Sepracor-Looks very promising
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Bob Swift who wrote (2864)5/19/1999 11:37:00 PM
From: rkrw  Read Replies (2) of 10280
 
<<<Despite being out to dinner,I still think one cannot rule out the possibility of a SGP licensing. SGP could licenses Nori but not seriously promoting it. That way Nori does not fall into the wrong hand(e.g.Glaxo) and SGP wipes out possible competition for DCL. >>>

If you think the FTC has a problem with the LLY deal, what do you think they would say to SGP given they already control well over 50% of the antihistamine market? The deal would be rejected under the Hart Scott Rodino Act before you could finish your dinner.
Further, sorry to say so, but I hardly think SGP is shaking in their boots at the competitive threat of nora.

Let's hope Sepr finds a powerful marketing partner that places a priority on it.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News